Evidence map›Paper›PMID 28143456›Full record

Trial reportBMC endocrine disorders2017

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.

Mojca Jensterle, Nika Aleksandra Kravos, Katja Goričar, Andrej Janez

2 registry-linked trialsOpen access · goldFull text readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC endocrine disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02909933. Cited by 45 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 10 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02909933 phase4completed

Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity

Ran2015Enrolled30Registered outcomes2Posted comparisons0ConditionsObesity, Polycystic Ovary SyndromeArmsliraglutide, metformin and liraglutide
Open the trial in the graph
NCT03352869 phase4completed

Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation

Ran2017Enrolled183Registered outcomes4Posted comparisons0ConditionsDisorder of Glucose Regulation, Overweight and Obesity, Polycystic Ovary SyndromeArmsexenatide, Metformin
PMID 24256515PMID 24362411PMID 25330463PMID 25880805PMID 18460557PMID 25726702other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 10 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pharmacological and non-pharmacological strategies for obese women with subfertility.The Cochrane database of systematic reviews · 2021 · on this map
    Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mojca JensterleDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška 7, Ljubljana, SI-1000, Slovenia.
Nika Aleksandra KravosDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška 7, Ljubljana, SI-1000, Slovenia.
Katja GoričarInstitute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, Ljubljana, 1000, Slovenia.
Andrej JanezDepartment of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška 7, Ljubljana, SI-1000, Slovenia. andrej.janez@kclj.si.
Ljubljana University Medical Centre · SIUniversity of Ljubljana · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiraglutide 3 mg was recently approved as an anti-obesity drug. Metformin is weight neutral, yet it could enhance the therapeutic index of GLP-1 agonist. We compared weight-lowering potential of liraglutide 1.2 mg in combination with metformin to liraglutide 3 mg monotherapy in obese PCOS.

methodsThirty obese women with PCOS (aged 33.1 ± 6.1 years, BMI 38.3 ± 5.4 kg/m

resultsBoth treatments led to significant weight loss (-3.6 ± 2.5 kg, p = 0.002 in COMBO vs -6.3 ± 3.7 kg, p = 0.001 in LIRA3). BMI and waist circumference reduction in LIRA3 was greater than in COMBO (-2.2 ± 1.3 vs -1.3 ± 0.9 kg/m

conclusionsShort-term interventions with COMBO and LIRA3 both led to significant improvement of measures of obesity in obese PCOS, LIRA3 being superior to COMBO. However, COMBO further improved androgen profile beyond weight reduction and was associated with better tolerability.

trial registrationThe study was retrospectively registered with ClinicalTrials.gov ( NCT02909933 ) on 16

Indexed as

AdultBiomarkersBlood GlucoseBody WeightDrug Therapy, CombinationFemaleFollow-Up StudiesGlycated HemoglobinHumansHypoglycemic AgentsLiraglutideMetforminObesityPilot ProjectsPolycystic Ovary SyndromePrognosisBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsLiraglutideMetforminLiraglutideMetforminObesityPCOS

Identifiers

PMID28143456
PMCPMC5286837
OpenAlexW2586042279

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.